Spots Global Cancer Trial Database for A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis
Official Title: A Randomized, Double-blind and Imitation, Parallel-control, Multicenter Phase II Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) With Bone Metastasis
Study ID: NCT04325776
Study Description
Brief Summary: AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met, suggesting that its anti-tumor effect mainly inhibits the activation of key downstream oncogenic pathways by inhibiting expression of c-met, tumor angiogenesis and tumor cell migration.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui Chest Hospital, Hefei, Anhui, China
Henan Cancer Hospital, Zhengzhou, Henan, China
China-Japan Union Hospital Of Jilin University, Changchun, Jilin, China
Jinzhou Central Hospital, Jinzhou, Liaoning, China
Shenyang Chest Hospital, Shenyang, Liaoning, China
Sir Run Run Shaw Hospital (SRRSH), Hangzhou, Zhejiang, China
The First Hospital of Jiaxing, Jiaxing, Zhejiang, China
Quzhou People's Hospital, Quzhou, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
